Literature DB >> 32454653

Development and in vitro Evaluation of Voriconazole Nanoparticle Formulation for Mucosal Application.

Seda Rençber1, Sinem Yaprak Karavana1.   

Abstract

OBJECTIVES: This study aimed to prepare and evaluate mucoadhesive nanoparticle formulations of voriconazole, an antifungal drug, for mucosal application. It was also aimed to develop and validate a HPLC method of voriconazole.
MATERIALS AND METHODS: In this study, mucoadhesive nanoparticles containing voriconazole were prepared using a coating polymer of chitosan. The obtained nanoparticles were characterized via particle size, polydispersity index, zeta potential measurement, and mucoadhesion studies. Drug loading capacity was tested for determination of the voriconazole amount in the nanoparticles. In vitro drug release was also examined. The HPLC method was validated for linearity, accuracy, precision (repeatability and reproducibility), specificity, stability, limits of detection (LOD), and limit of quantification (LOQ).
RESULTS: In vitro characterization results of the mucoadhesive nanoparticle formulation containing voriconazole was found to be appropriate with a small particle size of 217.1±4.2 nm, a narrow polydispersity index of 0.335±0.042, 99.052±0.424% drug loading, and a positive zeta potential value of +26.82±0.4 mV. Accor-ding to a mucoadhesive study, it can be concluded that the nanoparticle was able to interact with mu-cin due to ionic interaction. Also, the turbidity of nanoparticle/mucin dispersion was higher than the turbidity of mucin dispersion itself. Based on the in vitro drug release, no burst effect was observed, indicating that voriconazole was homogeneously dispersed in the nanoparticle dispersion and that no significant amount of drug was adsorbed onto the nanoparticle surface. The release was found to fol-low a non Fickian diffusion mechanism with first order drug release. The proposed HPLC method was simple, highly sensitive with good linearity, accurate, precise, specific, and stable, showing that the method is useful for routine quality control.
CONCLUSION: This study has shown that the mucoadhesive nanoparticle formulation containing voriconazole repor-ted here is a promising candidate for the local treatment of mucosal diseases. The developed HPLC method can be succesfully applied to pharmaceutical preparations containing voriconazole. ©Copyright 2018 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  HPLC; Voriconazole; chitosan; local application; mucoadhesive nanoparticle

Year:  2018        PMID: 32454653      PMCID: PMC7228014          DOI: 10.4274/tjps.54265

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  22 in total

1.  Rheological and mechanical properties of poloxamer mixtures as a mucoadhesive gel base.

Authors:  Esra Baloglu; Sinem Yaprak Karavana; Zeynep Ay Senyigit; Tamer Guneri
Journal:  Pharm Dev Technol       Date:  2010-08-17       Impact factor: 3.133

2.  1. Commentary on an exponential model for the analysis of drug delivery: Original research article: a simple equation for description of solute release: I II. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs, 1987.

Authors:  Nicholas A Peppas
Journal:  J Control Release       Date:  2014-09-28       Impact factor: 9.776

3.  Mucoadhesive films containing chitosan-coated nanoparticles: a new strategy for buccal curcumin release.

Authors:  Letícia Mazzarino; Redouane Borsali; Elenara Lemos-Senna
Journal:  J Pharm Sci       Date:  2014-09-03       Impact factor: 3.534

4.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

5.  Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery.

Authors:  Min Liu; Jian Zhang; Xi Zhu; Wei Shan; Lian Li; Jiaju Zhong; Zhirong Zhang; Yuan Huang
Journal:  J Control Release       Date:  2015-12-11       Impact factor: 9.776

6.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

7.  Hyaluronic acid-coated chitosan nanoparticles: molecular weight-dependent effects on morphology and hyaluronic acid presentation.

Authors:  Abdulaziz Almalik; Roberto Donno; Christopher J Cadman; Francesco Cellesi; Philip J Day; Nicola Tirelli
Journal:  J Control Release       Date:  2013-10-06       Impact factor: 9.776

8.  Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity.

Authors:  Angela M de Campos; Yolanda Diebold; Edison L S Carvalho; Alejandro Sánchez; Maria José Alonso
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

9.  Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.

Authors:  Ashish K Mehta; Khushwant S Yadav; Krutika K Sawant
Journal:  Curr Drug Deliv       Date:  2007-07       Impact factor: 2.565

10.  Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis.

Authors:  Seda Rençber; Sinem Yaprak Karavana; Fethiye Ferda Yılmaz; Bayri Eraç; Merve Nenni; Seda Özbal; Çetin Pekçetin; Hande Gurer-Orhan; Mine Hoşgör-Limoncu; Pelin Güneri; Gökhan Ertan
Journal:  Int J Nanomedicine       Date:  2016-06-10
View more
  1 in total

1.  Formulation, optimization, and nephrotoxicity evaluation of an antifungal in situ nasal gel loaded with voriconazole‒clove oil transferosomal nanoparticles.

Authors:  Ahmed K Kammoun; Alaa Khedr; Maha A Hegazy; Ahmed J Almalki; Khaled M Hosny; Walaa A Abualsunun; Samar S A Murshid; Rana B Bakhaidar
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.